Altimmune presents data at easl international liver congress™ 2024 supporting the disease modifying potential and differentiated therapeutic profile of pemvidutide in metabolic dysfunction-associated steatohepatitis (mash)

Follow-on analyses of non-invasive tests from phase 1 trials in metabolic dysfunction-associated steatotic liver disease (masld) suggest the potential for meaningful histologic improvements with mash biopsy readouts in q1 2025
ALT Ratings Summary
ALT Quant Ranking